Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A nurse shows vials of the anti-dengue vaccine at Parang Elementary School in Marikina, west of Manila on April 4, 2016. Photo: Noel Celis / AFP / Getty Images

School children in the Philippines are no longer receiving a vaccine for dengue virus after the manufacturer announced people were at risk for developing more severe cases of the disease if they hadn't been previously infected with the virus before immunization, reports the New York Times. The Dengvaxia vaccine by Sanofi Pasteur is currently the only licensed one for the virus in the world.

Why it matters: As many as 390 million people around the world are infected each year with dengue virus. Most who are treated can survive the disease but in some cases it turns into a hemorrhagic fever that can be deadly. In the Philippines, more than 730,000 school-aged children have been vaccinated with Dengvaxia as part of a nearly $70 million government-funded immunization program. It appears the Dengvaxia vaccine makes hemorrhagic fever more likely.

What's happening: There are four different groups or serotypes of dengue virus. People who recover from infection with one type are then immune to it. But some people can develop hemorrhagic fever if they are later infected with a different serotype. In the Philippines, about 200,000 people are infected with dengue each year, reports the NYT.

Earlier this week, Sanofi Pasteur announced a long-term study of the vaccine found while it protected people who had already been infected with dengue, "more cases of severe disease could occur following vaccination upon a subsequent dengue infection."

Concerns about the Philippines vaccine program emerged early on. Anthony Leachon from PhilHealth told the NYT there was "lingering uncertainty" about the vaccine as medical experts awaited long-term clinical trial results. "Evidence from manufacturer's trials shows that there may be a paradoxical increase in the incidence of severe dengue beginning a few years after children are vaccinated, and possibly continuing for the rest of their lives," he said.

The World Health Organization's position is that the dengue vaccine should only be administered in regions where there is a high burden of disease and to children over the age of 9. By then, most children in those areas will have already contracted the disease.

What's next: The program is being suspended while health officials monitor the children, none of whom have currently developed a severe form of the disease according to the country's Health Secretary Francisco Duque III.

Go deeper: Axios' Erin Ross on the dengue virus' complex relationship with the immune system.

Go deeper

Biden confronts mounting humanitarian crisis at the border

Illustration: Eniola Odetunde/Axios. Photo: Pool/Getty Images     

Just over a month into his presidency, President Biden is staring down a mounting crisis at the border that could be just as bad as the ones faced by Barack Obama and Donald Trump, if not worse.

Why it matters: Immigration is an issue that can consume a presidency. It's intensely and poisonously partisan. It's complicated. And the lives and welfare of vulnerable children hang in the balance.

Erica Pandey, author of @Work
2 hours ago - Economy & Business

The rise of vaccine passports

Illustration: Annelise Capossela/Axios

Vaccine passports were touted early in the pandemic as an important piece of the plan to get people back to normal life. Now they’re becoming a reality.

Driving the news: CLEAR, the secure digital identity app that you see in airports around the world, and CommonPass, a health app that lets users securely access vaccination records and COVID test results, have joined forces.

"Vaccine tourism" stretches states' supplies

Illustration: Sarah Grillo/Axios

Americans who are highly motivated to get vaccinated are traveling across state lines after hearing about larger vaccine supplies or loopholes in sign-up systems.

Why it matters: "Vaccine tourism" raises ethical and legal questions, and could worsen the racial socioeconomic and racial inequalities of the pandemic.